Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREXAFEMME is an oral small-molecule tablet approved by GSK in June 2021 for treatment in women's health. The specific indication and mechanism of action are not disclosed in available data, but the product name and female-focused positioning suggest a gynecological or reproductive indication. As an NDA small-molecule product, it represents targeted oral therapy in a specialized therapeutic area.
Peak12.8 years to LOE
Product is in peak commercial phase with no immediate competitive pressure, suggesting stable team headcount and established go-to-market operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BREXAFEMME offers career stability in a peak-stage product with no competitive threats, strong patent protection through 2039, and a specialized women's health focus. Limited publicly visible headcount suggests either a focused team structure or an undermarketed niche asset with growth potential.
Brand ManagerField Sales Representative
Worked on BREXAFEMME at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.